Archive

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses his presentation from the presidential session on genomic sequencing in this video. Also included article entitled ‘Genome-guided therapy in multiple myeloma’

Genome-guided therapy in multiple myeloma by Maria Dalby Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA Genomic sequencing of newly-diagnosed and refractory MM patients shows that combination therapy… read more.

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article ‘Risk stratification in the older patient: what are our priorities?’

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

ISH/BSH 2016: Professor Graham Jackson (Newcastle-Upon-Tyne, UK) discusses the risk factors and patient characteristics that most inform treatment selection for patients with R/R MM. Also included article 'Risk stratification in the older patient: what are our priorities?'

Risk stratification in the older patient: what are our priorities? by Maria Dalby Professor Sonja Zweegman, VU University Medical Centre, Amsterdam, NL Biological age and frailty, rather than… read more.

ISH / BSH 2016: A well attended joint ISH / BSH meeting in Glasgow brought together cutting edge research from both the UK and international myeloma community, whilst allowing lively debate on how best to implement recent advances within the environment of the NHS. Professor Paul G. Richardson (Boston, USA) and Professor Graham Jackson (Newcastle-Upon-Tyne, UK) give an international and British perspective on highlights from the meeting.

ISH / BSH 2016: Professor John Radford (The University of Manchester), Dr Graham Collins (Oxford University Hospitals) and Professor David Linch ( University College Hospital, London) give their highlights from this year’s BSH meeting in association with the 36th World Congress of the International Society of Hematology.

ECCO 2016: Professor Stefan Schreiber (Kiel, Germany) discusses some of the issues in managing Crohn’s disease.

In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.

ECCO 2016: Professor Stefan Schreiber (Kiel, Germany) discusses some of the issues in managing Crohn's disease.

In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.

ECCO 2016: Marian O’Connor (Harrow, UK) and Helen Terry (CCUK) discuss the importance of the IBD nurse, how the role has changed, how the UK had led the way and what the future holds for IBD nurses.

The future is now – importance of the IBD nurse in patient care. by Maria Dalby Marian O’Connor (St Mark’s Hospital, London, UK ), Silvio Danese (Milan, Italy)… read more.

ECCO 2016: Professor David Rubin (Chicago, USA), Dr Charlie Lees (Edinburgh, UK) and Dr Peter Irving (London, UK) discuss when to cycle biologics within class and when to switch classes for patients failing on anti-TNF therapy.

ECCO 2016: Dr Ailsa Hart (St Mark’s Hospital IBD Unit, Harrow, UK) discusses the issues raised at this year’s ECCO around cost effectiveness in IBD.

ECCO 2016: Helen Terry (CCUK Director of Policy, Research and Public Affairs, UK) discusses the impact on IBD care of involving patients in patient panels.